-CONTEPO is a potential first-in-class intravenous antibiotic in U.S. for the treatment of complicated urinary tract infections The NDA for CONTEPO was resubmitted based on the outcome and final ...

In a study, IV fosfomycin appeared less effective than IV ceftriaxone or meropenem for bacteremic UTI caused by multidrug-resistant E. coli, but the drug may be considered for selected patients with ...

Escherichia coli is the most common cause of bacterial prostatitis. Findings from a small study suggest it could be an effective, safe, and attractive alternative to fluoroquinolones, bacterial ...

SAN DIEGO — High cure rates can be achieved with fosfomycin in patients with chronic prostatitis — many of whom are resistant to the current first-line treatment of fluoroquinolones — according to ...

Review the side-effects of Fosfomycin as documented in medical literature. The term "side effects" refers to unintended effects that can occur as a result of taking the medication. In majority of the ...

DUBLIN, Ireland, June 19, 2020 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective ...

PGY-2 Critical Care and Pediatrics Pharmacy Resident, Albany Medical Center, Albany, New York Fosfomycin provides an appropriate treatment option for uncomplicated UTIs, with comparable clinical ...

MISSISSAUGA, ON / ACCESSWIRE / May 23, 2019 / Verity Pharmaceuticals announced today that, following a priority review, Health Canada has given a Notice of Compliance to their new antibiotic IVOZFO ...

Participants included 464 hospitalized adults with cUTI or AP diagnosis, randomly assigned to be administered either ZTI-01 or piperacillin/tazobactam for a fixed 7 ...

Researchers identified novel chromosomal mutations and described their role in the development of resistance of Escherichia coli (E. coli) to broad-spectrum antibiotic fosfomycin, according to ...

Prediction of early death risk in the elderly with cancer: Results of a prospective multicentric study of 364 patients under chemotherapy No significant financial relationships to disclose. This is an ...